Lantern Pharma Receives FDA Authorization To Initiate Its Phase 2 Clinical Trial, Harmonic, For LP-300 In Never Smokers With Non-Small Cell Lung Cancer
The Harmonic™ trial is a Phase 2 multi-center study focused on never smokers with advanced non-small cell lung cancer (NSCLC) and will begin patient enrollment during Q3 2022.
In a previous Phase 3